ReviewCancer Biomarkers

Beyond PSA: The Next Generation of Prostate Cancer Biomarkers

See allHide authors and affiliations

Science Translational Medicine  28 Mar 2012:
Vol. 4, Issue 127, pp. 127rv3
DOI: 10.1126/scitranslmed.3003180

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Next-Gen Biomarkers

For decades, the prostate-specific antigen (PSA) test has been used to assist in the diagnosis of prostate cancer. It has also become more prevalent in early cancer screening. Although the number of deaths related to prostate cancer has decreased, it is not clear that the PSA test has been the major factor. As Prensner and co-authors point out, the PSA test may “do more harm than good.” This Review focuses on new ways to address unmet clinical needs in the area of biomarkers, to hopefully add to the armamentarium of diagnostic, prognostic, and predictive tools for prostate cancer, including PSA.